CRVO

MKT CAP:$36M

CervoMed Inc.

Market Cap

$36M

Healthcare·Biotechnology·🇺🇸 United States·NASDAQ

Healthcare·Biotechnology·🇺🇸·NASDAQ

Stock Price

$3.85-$3.94 (-50.58%)

Apr 23, 2026

Company Details

CervoMed Inc., a clinical-stage biotechnology company, engages in the development and commercialization of drug treatments for neurodegenerative diseases. It develops neflamapimod, an orally administered small molecule brain penetrant for t...

CEO

John J. Alam

IPO Date

May 23, 2008

Website

www.cervomed.com

Key Metrics TTM

Revenue

$322.6K

— YoY

Net Income

-$27M

EPS (Diluted)

-$2.97

Free Cash Flow

-$23M

Revenue / Share

$0.03

Gross Margin

100.0%

Operating Margin

-8771.7%

Net Margin

-8359.9%

FCF Margin

-7269.8%

P/S

111.1x

P/E

—

Earnings Reports

Q1 2026

May 11, 2026

PENDING

FY 2025

Mar 13, 2026

$4MEPS -$2.98

Q4 2025

Mar 13, 2026

$0EPS -$0.87

Q3 2025

Nov 7, 2025

$322.6KEPS -$0.84

Q2 2025

Aug 8, 2025

$0EPS -$0.70

Revenue & Profitability

Quarter	Revenue	Gross Profit	Operating Income
Q1 22	$0	$0	-$5M
Q2 22	$0	$0	-$4M
Q3 22	$0	$0	-$904.1K
Q4 22	$0	$0	-$4M
Q1 23	$0	$0	-$1M
Q2 23	$0	$0	-$1M
Q3 23	$0	$0	-$3M
Q4 23	$0	$0	-$2M
Q1 24	$0	$0	-$3M
Q2 24	$0	$0	-$3M
Q3 24	$0	$0	-$5M
Q4 24	$0	$0	-$7M
Q1 25	$0	$0	-$5M
Q2 25	$0	$0	-$7M
Q3 25	$322.6K	$322.6K	-$8M
Q4 25	$0	$0	-$8M

Valuation

Quarter	P/S	P/E
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	—	—
Q1 24	—	—
Q2 24	—	—
Q3 24	—	—
Q4 24	—	—
Q1 25	—	—
Q2 25	—	—
Q3 25	362.1x	—
Q4 25	235.6x	—

Operating Cash Flow

Quarter	Operating CF	Free CF
Q1 22	-$5M	-$5M
Q2 22	-$4M	-$4M
Q3 22	$7M	$7M
Q4 22	-$3M	-$3M
Q1 23	-$1M	-$1M
Q2 23	-$2M	-$2M
Q3 23	$3M	$3M
Q4 23	-$3M	-$3M
Q1 24	-$1M	-$1M
Q2 24	-$2M	-$2M
Q3 24	-$5M	-$5M
Q4 24	-$8M	-$8M
Q1 25	-$4M	-$4M
Q2 25	-$7M	-$7M
Q3 25	-$6M	-$6M
Q4 25	-$7M	-$7M

Capital Expenditures

Quarter	CapEx
Q1 22	$0
Q2 22	$0
Q3 22	$2
Q4 22	$0
Q1 23	$2
Q2 23	$3
Q3 23	$5
Q4 23	$4
Q1 24	$0
Q2 24	$5
Q3 24	$0
Q4 24	$0
Q1 25	$0
Q2 25	$5
Q3 25	$0
Q4 25	$0

CapEx

OpEx vs Revenue Growth (YoY)

Quarter	Revenue Growth	OpEx Growth
Q1 22	—	-2.8%
Q2 22	—	+10.8%
Q3 22	—	-92.9%
Q4 22	—	+22.6%
Q1 23	—	-68.7%
Q2 23	—	-71.0%
Q3 23	—	+195.9%
Q4 23	—	-41.6%
Q1 24	—	+81.9%
Q2 24	—	+143.3%
Q3 24	—	+101.7%
Q4 24	—	+191.9%
Q1 25	—	+104.4%
Q2 25	—	+120.9%
Q3 25	—	+55.0%
Q4 25	—	+15.1%

Stock-Based Compensation

Quarter	SBC ($)	% of Revenue
Q1 22	$278.1K	—
Q2 22	$278.1K	—
Q3 22	$0	—
Q4 22	$189.9K	—
Q1 23	$71.2K	—
Q2 23	$62.3K	—
Q3 23	$0	—
Q4 23	$165.0K	—
Q1 24	$218.2K	—
Q2 24	$578.6K	—
Q3 24	$271.2K	—
Q4 24	$337.7K	—
Q1 25	$361.2K	—
Q2 25	$497.0K	—
Q3 25	$0	0.0%
Q4 25	$0	—

OpEx Breakdown

Quarter	R&D	G&A
Q1 22	$2M	$2M
Q2 22	$2M	$2M
Q3 22	$330.5K	$573.5K
Q4 22	$2M	$2M
Q1 23	$2M	$1M
Q2 23	$2M	$992.6K
Q3 23	$2M	$2M
Q4 23	$3M	$2M
Q1 24	$3M	$2M
Q2 24	$4M	$3M
Q3 24	$5M	$2M
Q4 24	$7M	$2M
Q1 25	$5M	$2M
Q2 25	$5M	$3M
Q3 25	$6M	$2M
Q4 25	$6M	$3M

War Chest

Quarter	Cash	Short-term Investments	Total
Q1 22	$10M	$23M	$33M
Q2 22	$6M	$23M	$29M
Q3 22	$7M	$19M	$26M
Q4 22	$4M	$0	$4M
Q1 23	$15M	$3M	$18M
Q2 23	$15M	$0	$15M
Q3 23	$10M	$0	$10M
Q4 23	$8M	$0	$8M
Q1 24	$6M	$0	$6M
Q2 24	$10M	$35M	$45M
Q3 24	$8M	$39M	$47M
Q4 24	$9M	$30M	$39M
Q1 25	$11M	$25M	$35M
Q2 25	$8M	$25M	$34M
Q3 25	$9M	$18M	$27M
Q4 25	$8M	$13M	$21M

Shares Outstanding

Quarter	Shares (Diluted)	QoQ Change	YoY Change
Q1 22	1M	+0.0%	+22.2%
Q2 22	1M	0.0%	+0.0%
Q3 22	1M	0.0%	+0.0%
Q4 22	1M	+0.1%	+0.1%
Q1 23	1M	0.0%	+0.1%
Q2 23	1M	0.0%	+0.1%
Q3 23	4M	+177.0%	+177.2%
Q4 23	6M	+50.7%	+317.3%
Q1 24	6M	+8.7%	+353.8%
Q2 24	9M	+41.0%	+539.9%
Q3 24	9M	0.0%	+131.0%
Q4 24	9M	0.0%	+53.4%
Q1 25	9M	0.0%	+41.0%
Q2 25	9M	+2.8%	+2.8%
Q3 25	9M	+3.4%	+6.3%
Q4 25	9M	0.0%	+6.3%

Shares Outstanding

Revenue Per Employee

Period	Revenue/Employee	Employees
Q1 22	—	—
Q2 22	—	—
Q3 22	—	—
Q4 22	—	—
Q1 23	—	—
Q2 23	—	—
Q3 23	—	—
Q4 23	$0	8
Q1 24	$0	8
Q2 24	$0	8
Q3 24	$0	8
Q4 24	$0	15
Q1 25	$0	15
Q2 25	$0	15
Q3 25	$21.5K	15
Q4 25	$0	700K

Revenue / Employee